Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.

[1]  A. Renslo,et al.  Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates. , 2018, Molecular pharmaceutics.

[2]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[3]  R. Orlowski,et al.  Proteasome inhibitors in cancer therapy , 2017, Nature Reviews Clinical Oncology.

[4]  Rémy Gébleux,et al.  Antibody-drug conjugates: Current status and future perspectives. , 2016, Pharmacology & therapeutics.

[5]  Feng Jiang,et al.  Linkers Having a Crucial Role in Antibody–Drug Conjugates , 2016, International journal of molecular sciences.

[6]  J. Cochran,et al.  Targeted Drug Delivery with an Integrin-Binding Knottin–Fc–MMAF Conjugate Produced by Cell-Free Protein Synthesis , 2016, Molecular Cancer Therapeutics.

[7]  Xiaodong Huang,et al.  Drugging the undruggables: exploring the ubiquitin system for drug development , 2016, Cell Research.

[8]  Antoine Maruani,et al.  Corrigendum: Recent advances in the construction of antibody-drug conjugates. , 2016, Nature chemistry.

[9]  Antoine Maruani,et al.  Recent advances in the construction of antibody-drug conjugates. , 2016, Nature chemistry.

[10]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[11]  R. Borzilleri,et al.  Antibody-drug conjugates: current status and future directions. , 2014, Drug discovery today.

[12]  Q. Dou,et al.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. , 2014, Current cancer drug targets.

[13]  B. Moore,et al.  Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor. , 2014, Chemistry & biology.

[14]  R. Chari,et al.  Antibody-drug conjugates: an emerging concept in cancer therapy. , 2014, Angewandte Chemie.

[15]  C. J. Murray,et al.  Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. , 2014, Bioconjugate chemistry.

[16]  Roger G. Linington,et al.  Molecular networking as a dereplication strategy. , 2013, Journal of natural products.

[17]  C. Crews,et al.  From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. , 2013, Natural product reports.

[18]  G. A. van der Marel,et al.  Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. , 2013, Journal of medicinal chemistry.

[19]  Andrew T. Fenley,et al.  The Carmaphycins: New Proteasome Inhibitors Exhibiting an α,β‐Epoxyketone Warhead from a Marine Cyanobacterium , 2012, ChemBioChem.

[20]  Bradley S Moore,et al.  Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. , 2012, Chemistry & biology.

[21]  D. Filippov,et al.  Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. , 2011, Chemistry & biology.

[22]  W. Gerwick,et al.  Biologically active secondary metabolites from marine cyanobacteria. , 2010, Current opinion in biotechnology.

[23]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[24]  L. T. Tan.  Filamentous tropical marine cyanobacteria: a rich source of natural products for anticancer drug discovery , 2010, Journal of Applied Phycology.

[25]  D. Nowis,et al.  Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach. , 2010, Journal of medicinal chemistry.

[26]  T. Long,et al.  Preparation of vinylglycines by thermolysis of homocysteine sulfoxides , 2009 .

[27]  S. Demo,et al.  Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). , 2009, Journal of medicinal chemistry.

[28]  John M. Beierle,et al.  Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures. , 2009, Journal of the American Chemical Society.

[29]  H. Ovaa,et al.  CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. , 2008, Blood.

[30]  Lik Tong Tan,et al.  Bioactive natural products from marine cyanobacteria for drug discovery. , 2007, Phytochemistry.

[31]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[32]  M. Pierschbacher,et al.  Incorporation of thioether building blocks into an αvβ3‐specific RGD peptide: Synthesis and biological activity , 2003 .

[33]  M. Pierschbacher,et al.  Incorporation of thioether building blocks into an alphavbeta3-specific RGD peptide: synthesis and biological activity. , 2003, Biopolymers.